Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin and Ursolic Acid in Prostate Cancer
NCT04403568Phase 1Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ursolic acid and curcumin in prostate cancer (PCa) (3 arms), sponsored by UT Health San Antonio. Primary endpoints: Number, frequency, duration, and relation of toxicity events, Peak serum concentration and 2 more. Planned start Oct 2021; status: withdrawn.
02
Drugs
ursolic acidcurcumin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04403568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04403568.